Special Topic of Glioblastoma

Published September 2011

A woman resident of the village of Doninos looks at the beach after new stains of fuel oil appeared overnight near her house north of El Ferrol in northern Spain on November 22, 2002. Thousands of birds, fish and wildlife have been affected after the Prestige tanker laden with 70,000 tonnes of fuel oil split in two and sank, triggering what ecologists said could become one of the world's worst oil spills.REUTERS/Desmond Boylan

Glioblastomas are one of the most common primary malignant brain tumors, and the most invasive. The causes of brain tumors are largely unknown. Some suspected risk factors include male gender, age over 50, ethnicity, having a low-grade astrocytoma, exposure to high doses of ionizing radiation, or having certain predisposing genetic disorders.

Top 20 Highly Cited Papers
10-Year Period | 2-Year Period
Time Series Graphs
( 1- & 5-Year Periods)

   

The features of this Special Topic outlined above represent distinct slices of citation data. By approaching citation data from multiple angles, we can observe trends and anomalies across categories—leading to more rich and nuanced stories behind the data.

The baseline time span for this database is (publication years) January 1, 2001-July 17, 2011. This analysis was created using the Web of Science® from Clarivate Analytics. The resulting database contained 11,433 (10 years) and 4,272 (2 years) papers; 38,541 authors; 83 nations; 1,357 journals; and 6,356 institutions. See additional information below in the overview & methodology sections.

 

Topic Overview


A bird stained with fuel oil sits on the shore near Russia's southern port of Kavkaz, November 12, 2007. Russian authorities launched a major rescue operation at the northern mouth of the Black Sea on Monday to save missing seamen and contain environmental damage after a storm sank at least four ships and split open a small oil tanker. REUTERS/Alexander Natruskin.
Gliobastoma (astrocytoma) WHO grade
IV - MRI coronal view, post contrast.
From the Wiki Commons.

Glioblastomas are one of the most common primary malignant brain tumors, and the most invasive. The National Cancer Institute estimates that there are 22,340 new cases of brain and other nervous system cancers diagnosed annually.1 According to the International RadioSurgery Association, about 13,000 Americans die from malignant brain tumors each year, accounting for about 2% of the cancer mortality rate.2

The causes of brain tumors are largely unknown. Some suspected risk factors include male gender, age over 50, ethnicity (Caucasians, Asians, and Latinos are at a higher risk), having a low-grade astrocytoma, exposure to high doses of ionizing radiation; or having certain predisposing genetic disorders such as neurofibromatosis, tuberous sclerosis, Von Hippel-Lindau disease, Li-Fraumeni syndrome, or Turcot's syndrome.3 Symptoms can include headache; nausea and vomiting; speech, sight, or hearing problems; motor and balance problems; changes in mood or personality; memory problems; seizures; and numbness in the extremities.4

Treatment options include surgery, radiotherapy, and chemotherapy. Prognosis, however, is generally poor. Although treatment can improve quality of life, patients do not tend to survive more than five years past diagnosis.3

1. http://www.cancer.gov/cancertopics/wyntk/brain/page3
2. http://www.irsa.org/glioblastoma.html
3. http://www.mountsinai.org/patient-care/health-library/diseases-and-conditions/glioblastoma-multiforme
4. http://www.cancer.gov/cancertopics/wyntk/brain/page5


Constructing the Database

In this analysis, Special Topics examines the literature on glioblastoma over the past decade and over the past two years. To construct the initial data pool, the keyword "glioblastoma*" was used to search titles, abstracts, and keywords of original articles, reviews, and proceedings papers published in the in the Web of Science® database from Clarivate Analytics between January 1, 2001 and July 17, 2011. To make the paper lists more on-point, we restricted to those articles containing the keyword "glioblastoma*" in the title.

INTERVIEWS MENU



Read interviews, first-person essays, profiles, and other features about people in a wide variety of fields, along with information on journals & institutions in the topic of Glioblastoma. All of the author comments below are also listed in the site-wide Author Commentaries listings (available by month/year or alphabetically).


JANUARY 2012
Henry Friedman Discusses the Quagmire of Glioblastoma

Henry S. FriedmanOur Special Topics analysis of glioblastoma research over the past decade shows that the work of Dr. Henry Friedman ranks at #6 by total papers and #15 by total cites, based on 89 papers cited a total of 3,894 times. Three of these papers rank among the top 20 papers over the past decade or over the past two years. In Essential Science IndicatorsSM his work includes 177 papers, the majority of which are classified in the field of Clinical Medicine, cited a total of 5,003 times between January 1, 2001 and August 31, 2011. In this interview, he talks with ScienceWatch.com correspondent Gary Taubes about his highly cited work.

 

DECEMBER 2011
Kenneth Aldape on Gene Expression Profiling in Glioblastoma

Kenneth AldapeOur Special Topics analysis of Glioblastoma research over the past decade shows that the work of Dr. Kenneth Aldape ranks at #3 by total papers and #14 by total cites, based on 91 papers cited a total of 3,951 times. In Essential Science IndicatorsSM from Clarivate Analytics, he ranks among the top 1% of researchers in the field of Clinical Medicine. In this interview below, ScienceWatch.com correspondent Gary Taubes talks with Aldape about his research concerning glioblastoma.

 


NOVEMBER 2011
Michael Weller Discusses the Role of TGF-beta in Glioblastoma

Michael WellerOur Special Topics analysis of Glioblastoma research over the past decade shows that the work of Prof. Dr. Michael Weller ranks at #1 by total papers and #2 by total cites, based on 128 papers cited a total of 7,149 times. In Essential Science IndicatorsSM from Clarivate Analytics, his work appears in the top 1% in the field of Clinical Medicine and Neuroscience & Behavior. In this interview, ScienceWatch.com correspondent Gary Taubes talks with Weller about his highly cited work as it relates to glioblastoma.

 


OCTOBER 2011
Roger McLendon on Solving the Jigsaw Puzzle of Glioblastoma

Roger E. McLendonAccording to our Special Topics analysis of Glioblastoma research over the past decade, the work of Dr. Roger McLendon ranks at #5 by total cites and #12 by total papers, based on 73 papers cited a total of 5,311 times during the analysis period. Four of these papers rank among the 20 most-cited over the past decade or over the past two years in Essential Science IndicatorsSM from Clarivate Analytics, he ranks in the top 1% among scientists in the field of Clinical Medicine. Here, ScienceWatch.com talks with McLendon about his highly cited work as it relates to glioblastoma.

Thresholds



Once the database was in place, it was used to generate list of authors, journals, institutions, and nations. Rankings for author, journal, institution, and country are listed in three ways: according to total cites, total papers, and total cites/paper*. The paper thresholds and corresponding percentages used to determine scientist, institution, country, and journal rankings according to total cites/paper, and total papers respectively are as follows:

Entity Authors Institutions Journals Nations
Thresholds 15 61 16 18
Percentage: %1 %1 %10 %50
*Unless otherwise specified, all rankings have a >= 5 paper threshold for all measures.

Methodology



The baseline time span for this database is (publication years) January 1, 2001-July 17, 2011. This analysis was created using the Web of Science® from Clarivate Analytics. The resulting database contained 11,433 (10 years) and 4,272 (2 years) papers; 38,541 authors; 83 nations; 1,357 journals; and 6,356 institutions. See additional information below in the overview & methodology sections.

Keywords



The Internet search terms for this Topic are:

GLIOBLASTOMA, RADIOTHERAPY, CONCOMITANT, ADJUVANT, TEMOZOLOMIDE, MGMT GENE SILENCING, GLIOBLASTOMA MULTIFORME, GENOMIC ANALYSIS, MICRORNA-21, TUMORIGENESIS, APOPTOSIS, STEM-LIKE NEURAL PRECURSORS, EGFR KINASE INHIBITORS, AZD2171, PAN-VEGF RECEPTOR TYROSINE KINASE INHIBITORS, TUMOR VASCULATURE, EDEMA, PROGNOSIS, RESECTION, SURVIVAL, SMAD, FORKHEAD, CELL PROLIFERATION, TUMOR STEM CELLS, BFGF, EGF, PHENOTYPE, GENOTYPE, BEVACIZUMAB, IRINOTECAN, RECURRENCE, CHEMORESISTANCE, CDI33(+) CANCER STEM CELLS, GEFITINIB, INSULIN-LIKE GROWTH FACTOR RECEPTOR I, ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR, PHOSPHOINOSITIDE 3-KINASE SIGNALING, TEMSIROLIMUS, EORTC-NCIC TRIAL, CLINICALLY RELEVANT SUBTYPES, PDGFRA, IDH1, NF1, ERLOTINIB, GLIOSARCOMA, CARMUSTINE, TUMOR-INITIATING CELLS, SSEA-1, MOLECULAR PREDICTORS, GERMAN GLIOMA NETWORK, VASCULAR NORMALIZATION INDEX, CEDIRANIB, BEAD-BASED PROFILING, TYROSINE KINASE PHOSPHORYLATION, SOX2 SILENCING, TUMORIGENICITY, LIF, SIGNAL TRANSDUCTION PATHWAYS, HYPOXIC MICROENVIRONMENT.

Reuters PictureS and Featured Images


Toby Melville.
A visitor views butterfly pupae at the Natural
History Museum in London March 31, 2010.
REUTERS/Toby Melville.

Some of the images throughout the Special Topic of Glioblastoma are from Reuters Pictures. Other images used are credited and linked to their source.


About Reuters Pictures

This site includes material which is copyright 2011 Reuters. All rights reserved.

Republication or redistribution of Reuters content, including by framing or similar means, is prohibited without the prior written consent of Reuters.

Reuters and the Reuters logo are registered trademarks, and trademarks of the Clarivate Analytics group of companies.

For additional information on Reuters photographic services, please visit the web site at http://pictures.reuters.com.

 

Featured Image: Tamas Freund holds a human brain at the Institute of Experimental Medicine of Hungarian Academy of Science in Budapest. REUTERS/Laszlo Balogh.

   |   BACK TO TOP